Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cannabis capsules tested for joint pain relief in new study

NCT ID NCT06878417

Symptom relief Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tests whether daily cannabis extracts (CBD or THC) can reduce pain interference in people with hip or knee osteoarthritis. One hundred adults aged 40-80 will take either CBD, THC, or a placebo capsule daily for 8 weeks and track their symptoms remotely. The goal is to see if a larger trial is possible, not to prove the treatment works yet.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 40-80 years 2. Diagnosed with hip and/or knee osteoarthritis as per the American College of Rheumatology criteria 3. Experiencing moderate to severe pain interference as indicated by a PROMIS-PI SF-6a T-score ≥ 60 4. Have not initiated any new analgesics or osteoarthritis treatments in the previous 4 weeks 5. Able to self-report, understand and read English or French Exclusion Criteria: 1. Hip or knee surgery planned in the coming 4 months, 2. Injection into the affected joint(s) within the past 3 months (e.g., cortisone, plasma-rich protein, etc.), 3. Planned injection into the affected joint(s) during trial period, 4. Inflammatory arthritis (e.g., rheumatoid arthritis, Psoriatic arthritis, gout, etc.), 5. Contraindications to taking cannabis/cannabinoids, 6. Used nabilone or nabiximols in the last 30 days, 7. Used cannabis (medical or recreational) in the last 30 days (to allow sufficient washout), 8. A history of diagnosed cannabis use disorder or dependence, 9. Active substance use disorder, 10. Current DSM-V diagnosis of bipolar disorder, major depression, or psychosis, 11. An uncontrolled medical or major psychiatric disorder, 12. Currently on warfarin, 13. Known pregnancy or currently breastfeeding, 14. Men and women planning a pregnancy during the study or in the 12 weeks after stopping IPs 15. No fixed address or a plan to change addresses in the coming 4 months, 16. Known or suspected allergy to palm/coconut oil

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoarthritis of hip are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

osteoarthritis susceptibility 5 osteoarthritis susceptibility 6 osteoarthritis, hip osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Osteoarthritis of knee Osteoarthritis, hip

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • McGill University Health Centre/Montreal General Hospital

    RECRUITING

    Montreal, Quebec, H3G 1A4, Canada

  • University Health Network

    RECRUITING

    Toronto, Ontario, M5G 2C4, Canada

  • Women's College Hospital

    RECRUITING

    Toronto, Ontario, M5S 1B2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.